header logo image

Angelini Ventures Co-Leads $45 Million Series B Financing of Nuevocor to Advance Transformative Treatment for Genetic Dilated Cardiomyopathy

May 6th, 2025 2:46 am

Angelini Ventures marks its first investment in the cardiovascular and gene therapy space – and first in Asia, further diversifying its strong and growing portfolio

Read more:
Angelini Ventures Co-Leads $45 Million Series B Financing of Nuevocor to Advance Transformative Treatment for Genetic Dilated Cardiomyopathy

Related Posts

Tags:

Comments are closed.


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick